Press Release July 15, 2021

Kriya Therapeutics Closes $100 Million Series B

The Life Sciences team advised Kriya Therapeutics on the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies. The financing was led by Patient Square Capital, with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others. All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and the Juvenile Diabetes Research Foundation T1D Fund.

Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.

Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed and manufactured – improving speed to market and delivering significant reductions in the cost per dose. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™).

The Goodwin team was led by Deepa M. Rich and Sam Zucker with invaluable support from William “Wynn” Stateman, Steven Green, Chris Denn and Samira Seraji.

For additional details on the financing, please read the press release.